Molecular Profiling of Direct Xenograft Tumors Established from Human Pancreatic Adenocarcinoma After Neoadjuvant Therapy

[1]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[2]  Jeffrey E. Lee,et al.  Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation , 2010, Annals of Surgical Oncology.

[3]  Douglas B. Evans,et al.  Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice , 2009, Nature Protocols.

[4]  A. Sood,et al.  Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells , 2008, Clinical Cancer Research.

[5]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jeffrey E. Lee,et al.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Douglas B. Evans,et al.  Development of an Integrated Biospecimen Bank and Multidisciplinary Clinical Database For Pancreatic Cancer , 2008, Annals of Surgical Oncology.

[8]  G. Gallick,et al.  Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells , 2007, Annals of Surgical Oncology.

[9]  W. Scheithauer,et al.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Moses,et al.  Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. , 2006, Genes & development.

[12]  Gerald C. Chu,et al.  Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. , 2006, Genes & development.

[13]  R. Kurzrock,et al.  Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells , 2006, Molecular Cancer Therapeutics.

[14]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Hruban,et al.  An In vivo Platform for Translational Drug Development in Pancreatic Cancer , 2006, Clinical Cancer Research.

[16]  R. Kurzrock,et al.  Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. , 2006, Molecular cancer therapeutics.

[17]  M. Pino,et al.  Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. , 2005, Cancer research.

[18]  S. Ashley,et al.  RNA Interference Demonstrates a Novel Role for Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine Chemoresistance , 2005, Clinical Cancer Research.

[19]  S. Ashley,et al.  Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells , 2004, Clinical Cancer Research.

[20]  Richard Simon,et al.  A random variance model for detection of differential gene expression in small microarray experiments , 2003, Bioinform..

[21]  Daniel G Haller,et al.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[23]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Hruban,et al.  Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. , 1998, Cancer research.

[25]  P. Cohen,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism* , 1997, The Journal of Biological Chemistry.

[26]  S. Goodman,et al.  Tumor-suppressive pathways in pancreatic carcinoma. , 1997, Cancer research.

[27]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[28]  F. Guadagni,et al.  A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.